Kristen Riemenschneider represents life sciences companies on their most significant transactions, from strategic license and collaboration transactions to complex supply chain arrangements. She has a deep technical understanding of the life sciences industry, and has negotiated agreements in respect of cutting-edge technologies including gene editing and cell therapies.
Vinita Kailasanath has extensive experience in strategic intellectual property and data-driven transactions in life sciences and technology, and particularly at their intersection. She has represented life sciences companies, technology companies, healthcare companies and providers, and investors in connection with the execution of their cutting-edge MedTech and digital health strategies in addition to their other complex licenses and collaborations, strategic investments, and R&D and supply agreements.
Freshfields has an exceptional cross-border practice and depth of experience in the life sciences sector. I am eager to collaborate with my colleagues to assist our clients as they navigate increasingly complex technical and legal challenges on a global scale.14 November 2021
I am excited to join Freshfields’ globally integrated practice, which provides a powerful platform for supporting our clients’ digital health and medical technology transactions, wherever they occur around the world. I look forward to contributing to the team’s continued success.14 November 2021